DISCLAIMER
DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.
GlaxoSmithKline's Flu Vaccine Arepanrix Approved In Japan
GlaxoSmithKline PLC's (GSK) Japanese unit said Wednesday it has received approval from the Japanese government for its influenza vaccine Arepanrix H1N1 designed to be effective against swine flu.
GSK already has an agreement with the Japanese government to supply 74 million doses of Arepanrix H1N1, which is the first imported vaccine approved in Japan to cope with the swine flu outbreak.
Stephen Pierce is offering his book "Make Real Money on the Internet" absolutely free! Get your copy today!!
Posts
No comments:
Post a Comment